We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gene Editing Dramatically Improves Inherited Kidney Disease in Mice
News

Major Progress in Correcting Genetic Kidney Disease

Gene Editing Dramatically Improves Inherited Kidney Disease in Mice
News

Major Progress in Correcting Genetic Kidney Disease

Image credit: Pixabay
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gene Editing Dramatically Improves Inherited Kidney Disease in Mice"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

For the first time scientists have identified how to halt kidney disease in a life-limiting genetic condition, which may pave the way for personalised treatment in the future.

Experts at Newcastle University, UK, have shown in a cell model and in a mouse model that gene editing could be used for Joubert syndrome to stop kidney damage in patients who have the CEP290 faulty gene.

Joubert syndrome is a brain disorder, causing varying degrees of physical, mental and sometimes visual impairments. The condition affects approximately one in 80,000 newborns, and one third also get kidney failure.

Not all patients with Joubert syndrome carry the CEP290 gene, but those who do will develop kidney disease during their lifetime and may require a transplant or dialysis.

The study, which was funded by Kidney Research UK, has found it is possible to use a strand of engineered DNA to trick the cells' own editing machinery to bypass the CEP290 mutation that causes kidney damage - a technique known as 'exon-skipping'.

Professor John Sayer, from the Institute of Genetic Medicine, Newcastle University, led the research that is published online today (Friday, November 16) in the Proceedings of the National Academy of Sciences (PNAS).

He said: "This is the first time that gene editing within the kidney has been performed, even in a mouse model, as the design and delivery of the gene editing to the kidney has previously been thought to be too difficult.

"Our research is a major step forwards as we now know how we may be able to offer a therapy that corrects the gene mistake within kidney cells and prevent the development of genetic kidney disease.

"This work paves the way towards personalised genetic therapies in patients with the inherited kidney disease."

The European study used kidney cells from patients with Joubert syndrome and a mouse model to progress the research.

Experts used urine samples to grow kidney cells in the laboratory to see how the cells responded to gene editing. They also performed gene editing to halt kidney disease in a mouse that had Joubert syndrome and rodents suffering from kidney cysts and kidney failure.

Challenging disease

Professor Sayer, a Consultant Nephrologist at Newcastle Hospitals NHS Foundation Trust, said: "The treatment of genetic kidney disease is challenging, as this requires both the correction of the underlying gene defect and the delivery of the treatment.

"We have shown that the kidney disease in a mouse can be dramatically improved using this exon-skipping gene editing technology.

"This will mean that we can edit out genetic mistakes that are leading to inherited kidney diseases such as Joubert syndrome and we are testing this technology in other mouse models before we move into patient studies.

"We expect that we will start to test treatment of patients with exon-skipping within the next three years."

Scientists are now looking to work with a drug manufacturing company to bring the exon-skipping technology into patients' clinics.

This article has been republished from materials provided by Newcastle University. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:

Ramsbottom, S. A., Molinari, E., Srivastava, S., Silberman, F., & Sayer, J. A. (2018). Targeted exon skipping of a CEP290 mutation rescues Joubert syndrome phenotypes in vitro and in a murine model. Proceedings of the National Academy of Sciences of the United States of America. Retrieved from http://www.pnas.org/content/early/2018/11/15/1809432115

Advertisement